Oral Peptide Drugs Are Coming: How AI Could Transform Peptide Therapy Beyond Injections
The article is based primarily on current FDA, NIH/PubMed and university research, including FDA prescribing information for oral semaglutide, Phase 3 research on the oral peptide icotrokinra, Stanford's computational peptide-discovery research, and 2025–2026 studies on AI-assisted peptide design and oral-delivery barriers.
